Pfizer’s Capsugel sales to KKR for $2.4 bn raises speculation on other divestment
This article was originally published in Scrip
Executive Summary
Pfizer has agreed to sell its Capsugel manufacturing business to private equity group KKR for $2.38 billion in cash, and said it will buy back additional shares.